Overview

• Barclays initiated coverage at overweight with a $146 price target, framing Oklo as a leveraged way to gain SMR exposure and noting a backlog of nonbinding agreements.
• Shares rose after Oklo announced a strategic partnership with Sweden's Blykalla AB covering SMR technology collaboration, supply chain coordination, and regulatory insights.
• Oklo said it will invest about $5 million in Blykalla's next funding round as it looks to expand its European footprint.
• The company remains pre-revenue and lacks U.S. Nuclear Regulatory Commission design approval, with analysts cautioning that operations are still years away.
• Recent milestones include selection by the U.S. Air Force for an Alaska modular-reactor project in June and a DOE-backed Aurora groundbreaking in Idaho this month, while shares have swung sharply after insider sales and valuation concerns.